Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. - Wikidata - awgldk - TriplyDB

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

http://www.wikidata.org/entity/Q52035993

about

Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo The sour side of neurodegenerative disorders: the effects of protein glycation.Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease.PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT Mechanisms of tau-induced neurodegeneration.Biological heterogeneity in ADNI amnestic mild cognitive impairment.Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APPSwe Mouse Models of Tauopathy and Amyloidosis.SOCIAL ENVIRONMENTAL RISK AND PROTECTION: A TYPOLOGY WITH IMPLICATIONS FOR PRACTICE IN ELEMENTARY SCHOOLS.CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.Developing pharmacological therapies for Alzheimer disease.Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.Advances in tau-based drug discovery.CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques.The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification Tau phosphorylation and aggregation in Alzheimer's disease pathology.Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.Use of okadaic acid to identify relevant phosphoepitopes in pathology: a focus on neurodegeneration Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.Does Alzheimer's disease begin in the brainstem?Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography.Intracellular and extracellular tau.Opportunities and challenges in developing Alzheimer disease therapeutics.Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife Tau and neurodegenerative disease: the story so far.Design, Synthesis and Evaluation of Novel Tacrine-Ferulic Acid Hybrids as Multifunctional Drug Candidates against Alzheimer's Disease.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease.Alzheimer's disease, a multifactorial disorder seeking multitherapies.Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.On-line capillary electrophoresis derivatization method for high sensitivity analysis of ubiquitin in filtered cerebrospinal fluid.Beneficial Effect of Flavone Derivatives on Aβ-Induced Memory Deficit Is Mediated by Peroxisome Proliferator-Activated Receptor γ Coactivator 1α: A Comparative Study.Unilateral injection of Aβ25-35 in the hippocampus reduces the number of dendritic spines in hyperglycemic rats.The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

P2860

Q24563378-895FF934-51B6-4C24-B0A8-EA4531FDEA31 Q24631720-A9CD92B3-1BBE-44AD-8D47-9A4CB8D87BC4 Q26853347-2A308B23-5456-4D56-A0C9-082AFC6F105E Q28386141-8DA7A3CE-D400-4D23-AB4C-A75B689029D0 Q30386079-AB7DCBDD-7AEB-45FB-A554-D362D69E74AA Q33756751-A65A4EA2-CF29-4992-B070-05D2515E4EC2 Q33818120-F581DCA5-EBB5-4948-BA23-99E2BDDC857A Q33859830-52602F96-AAE6-4A3B-8CA5-A1C68DC6EEF3 Q33882478-AADD4713-0389-40E3-8482-C1CEF92EC54F Q33903715-0BE77835-03C1-4AFB-9815-991F678D59C6 Q35059412-CEDF58FD-10B4-4839-85E5-94132140CEC3 Q35114771-010A52FC-28B6-421D-AB44-0D027B0444CA Q35114786-8F9824DC-C895-4E51-BB04-287BF8577CC0 Q35114797-8E1AE701-39AA-40E1-A0F7-73080F35C7F3 Q35321539-72C7C30E-873C-455F-BF9F-EAB3ABCD406E Q35579229-BC0B6629-DF25-4646-A588-A822E63E8E55 Q35588860-C43A52C4-03A1-4ABE-B6B0-95FB2B55B045 Q35946218-D2336E41-0C90-4E19-A844-E09437A09D1D Q36418199-BA0F8D59-CE18-42C8-9CDC-9771F98B1274 Q36929023-013C8A0A-1171-46AE-A12E-90A308967981 Q36999161-6E663733-8228-4BF9-B33C-06F10EE44C49 Q37178894-6893998E-4D4C-415D-AA7E-B3B70767219E Q37273675-39D6E1C7-B580-41F5-A01C-BA40509B81DB Q37456054-FF8C249A-1F43-470F-8332-3A811209721B Q37573818-6DA35893-1E02-4C1C-9A06-EA8129FC7610 Q37775895-800308F8-BB5B-44BF-B315-1CDD13353659 Q37940825-A604F61F-476F-4793-AC0F-D04A7B5098CF Q38175453-D0E82296-CB82-4CCF-A391-99A4ECDA2D60 Q38177975-71245F0C-B6AE-496A-B05D-57684DE443A6 Q38391075-FD1A6CC5-00F7-44D7-801A-F8DF6206E70C Q38658752-6A2519AE-1EFD-4ABF-9116-C6F57E8C82B2 Q38741686-18AF0878-F7CA-4D7A-A4DE-65A217CB8916 Q38979999-4FE52E3C-1549-4FDF-9EC9-D27F1386E2CD Q39326552-AD435B70-0225-40A3-BA03-3F4FDE7DE27D Q42418656-163F90A6-00F1-442E-A56D-73855C23DEFC Q47896160-28D25440-0195-44E5-91FF-26D29E45B924 Q48001827-C91A5A3B-98FB-43D7-A704-04461ACC5390 Q48178828-C888FC8D-CBF2-41A4-9E0E-B48DF1844115 Q48645083-18015840-2B24-41C8-A8F0-28B2423DD97F Q48670660-2806A837-ED7A-4850-AABD-57867CFDB365

P2860

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

http://www.wikidata.org/entity/Q52035993

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@en

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@nl

type

label

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@en

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@nl

prefLabel

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@en

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@nl

P1433

Q52035993-36F28FC9-CB17-4D78-83AF-64499BD9DE4E

P1476

Q52035993-40936753-C428-493C-A0B8-53D640FD0689

P2093

Q52035993-0BABEF34-2233-4BFD-A6AA-D83735C91F3D

Q52035993-167D2911-AA6F-4763-89CB-CCE60E788213

Q52035993-27247B05-9C23-4AA4-A03B-4645AE40E83D

Q52035993-5A7BDCB9-400D-4F4D-923D-E30D2C0CB72D

Q52035993-90ADD3A0-2F8A-4978-9E87-249F6D207D41

Q52035993-B23240AA-5F32-4AB8-B65E-36CF87CBC11D

Q52035993-F20460DF-3D34-4011-BC4E-E89552C2833E

P2860

Q52035993-066DC585-AF5C-46DE-B2B3-F11C178E17AA

Q52035993-0779D7CF-3B5F-410B-B0E8-04D136AD42ED

Q52035993-277F5820-2162-401B-ABA7-B36595E166B2

Q52035993-48BEAE25-B7EB-4148-BDEF-004D41BE2C30

Q52035993-7B8C9ACA-5C07-4D82-859C-2544AEBB9823

Q52035993-B6F2DBED-08CF-4844-9680-F090C56D8265

P304

Q52035993-6F75F246-DBA9-4D0B-9EF0-AAFCC8052312

P31

Q52035993-B0D2069C-F50F-4BBF-A30F-9DC59784E33C

P356

Q52035993-8305223F-35FB-499D-843C-922458F54FBB

P433

Q52035993-C6592340-050C-4443-A5DB-7725239AFBDE

P478

Q52035993-F7A2A77D-4EB1-4160-8739-277C35EA5D82

P50

Q52035993-A5DE4F13-2EF5-42E5-B34F-D282881FD126

Q52035993-A62E8A31-D242-40A6-BDBA-6574F77B74EC

Q52035993-B7A15E34-DE10-4A31-849C-1F55D33370FB

Q52035993-C43BBC99-0049-40A3-B30F-DE5C48DBC258

P577

Q52035993-4D4E33D7-6B65-453D-B22E-DBEA3F36E459

P698

Q52035993-2FBA716E-DCE6-4DA9-8CFB-8C1A13F1643D

P921

Q52035993-5C5841A6-88BB-4EF0-9068-F7F3FCA815BF

P356

P1433

Annals of Neurology

P1476

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

@en

P2093

Irina Alafuzoff

http://www.w3.org/2001/XMLSchema#string

Khalid Iqbal

http://www.w3.org/2001/XMLSchema#string

Maarit Lehtovirta

http://www.w3.org/2001/XMLSchema#string

Michael Flory

http://www.w3.org/2001/XMLSchema#string

Niels Andreasen

http://www.w3.org/2001/XMLSchema#string

Sabiha Khatoon

http://www.w3.org/2001/XMLSchema#string

Tuula Pirttila

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment.

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

P304

748-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.20639

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Eugeen Vanmechelen

Hilkka Soininen

Inge Grundke-Iqbal

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16247771

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid